Nov-18-20 Downgrade
BTIG Research
Buy → Neutral
Sep-22-20 Downgrade
Guggenheim
Buy → Neutral
Sep-08-20 Initiated
Citigroup
Buy
$80
May-14-20 Downgrade
JP Morgan
Overweight → Neutral
$58 → $50
Apr-01-20 Resumed
BofA/Merrill
Neutral
$51
Feb-20-20 Initiated
Guggenheim
Buy
$66
Feb-18-20 Downgrade
Barclays
Equal Weight → Underweight
$45
Nov-01-19 Downgrade
Barclays
Overweight → Equal Weight
$37 → $45
Jul-22-19 Initiated
Piper Jaffray
Overweight
$55
Feb-27-19 Upgrade
JP Morgan
Neutral → Overweight
Jan-23-19 Downgrade
JP Morgan
Overweight → Neutral
Oct-31-18 Initiated
ROTH Capital
Buy
Jul-16-18 Initiated
JP Morgan
Overweight
$36
Jul-16-18 Initiated
BofA/Merrill
Neutral
$24
Jul-16-18 Initiated
Barclays
Overweight
$32
Jan-13-21 04:30PM
Jan-12-21 09:30AM
Jan-08-21 08:30PM
Jan-06-21 04:54PM
Jan-05-21 11:26AM
Jan-04-21 11:42AM
07:30AM
Jan-03-21 02:20PM
Jan-02-21 07:30AM
Dec-30-20 08:49PM
10:04AM
Dec-29-20 11:15AM
Dec-28-20 08:20PM
09:15AM
Dec-26-20 01:55PM
10:05AM
Dec-24-20 10:45AM
09:09AM
Dec-23-20 09:00PM
Dec-19-20 04:17PM
Dec-18-20 10:12PM
Dec-17-20 11:08PM Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, EIDX, CIT, EMIS, FCNCA, FCNCB, EV, MS, NAV, STND, and WTRE PR Newswire
Dec-16-20 01:14PM
10:10AM
Dec-14-20 08:42PM
09:10AM
Dec-12-20 09:12AM
Dec-11-20 09:13PM
08:52PM
Dec-05-20 05:06AM
Dec-04-20 08:51PM
08:00PM
11:48AM
Dec-02-20 12:03PM
Nov-25-20 10:32PM
08:01AM
Nov-23-20 08:31PM
Nov-20-20 09:34PM
08:30PM
Nov-19-20 06:36PM
Nov-13-20 10:35PM
08:00PM
07:01PM
12:30PM
08:01AM
Nov-12-20 01:40PM
Nov-09-20 06:15PM
Nov-07-20 07:49PM
Nov-06-20 11:27PM
08:00PM
08:01AM Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc., BMC Stock Holdings, Inc., Callaway Golf Company, Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., Watford Holdings Ltd. and Yintech Investment Holdings Limited PR Newswire
Nov-05-20 10:53AM
07:30AM
Nov-03-20 10:39AM
Oct-31-20 06:57PM
Oct-30-20 09:41PM
03:31PM
Oct-29-20 04:30PM
Oct-27-20 10:15AM
Oct-26-20 06:54PM
01:37PM
Oct-24-20 02:10PM
Oct-23-20 04:44PM Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., MyoKardia, Inc. Watford Holdings Ltd. and Yintech Investment Holdings Limited PR Newswire
Oct-22-20 08:37PM
07:17PM
05:00PM
Oct-21-20 10:20PM
06:48PM
08:25AM
Oct-20-20 06:00PM
03:12PM
10:00AM
Oct-19-20 03:24PM
09:10AM
Oct-17-20 02:05PM
Oct-15-20 04:23PM
12:07PM
10:45AM
Oct-14-20 07:00PM
06:52PM
03:09PM
01:14PM
09:45AM
Oct-13-20 08:20PM
12:40PM
08:03AM
Oct-12-20 07:40PM
09:15AM
08:00AM
Oct-09-20 06:23PM
02:38PM
11:19AM
09:00AM
08:01AM Lifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), BMC Stock Holdings, Inc., Builders FirstSource, Inc., Cancer Genetics, Inc., Cellular Biomedicine Group, Inc., Eidos Therapeutics, Inc., Montage Resources Corporation, MyoKardia, Inc. and Yintech Investment Holdings Limited PR Newswire
Oct-08-20 04:00PM
09:00AM
Oct-07-20 08:05PM
06:30PM
05:36PM
10:10AM
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sinha Uma Chief Scientific Officer Jan 13 Sale 124.32 10,000 1,243,179 306,525 Jan 15 04:05 PM Valle Franco Senior Vice President, Finance Jan 12 Option Exercise 7.24 1,747 12,648 1,747 Jan 13 04:05 PM Valle Franco Senior Vice President, Finance Jan 12 Sale 125.45 1,747 219,152 0 Jan 13 04:05 PM Valle Franco Senior Vice President, Finance Jan 11 Option Exercise 7.24 1,500 10,860 1,500 Jan 13 04:05 PM Valle Franco Senior Vice President, Finance Jan 11 Sale 125.61 1,500 188,408 0 Jan 13 04:05 PM Turtle Cameron Chief Business Officer Dec 15 Option Exercise 13.84 26,294 363,995 76,915 Dec 16 07:27 PM Turtle Cameron Chief Business Officer Dec 15 Sale 111.77 26,294 2,938,796 50,621 Dec 16 07:27 PM Sinha Uma Chief Scientific Officer Dec 02 Sale 90.04 5,000 450,187 316,525 Dec 04 05:34 PM Turtle Cameron Chief Business Officer Nov 11 Sale 74.51 13,410 999,227 52,121 Nov 13 05:00 PM Valle Franco Senior Vice President, Finance Nov 09 Option Exercise 7.24 1,623 11,751 1,623 Nov 10 04:05 PM Valle Franco Senior Vice President, Finance Nov 09 Sale 74.93 1,623 121,609 0 Nov 10 04:05 PM Turtle Cameron Chief Business Officer Nov 02 Option Exercise 14.47 7,500 108,500 78,031 Nov 03 04:05 PM Turtle Cameron Chief Business Officer Nov 02 Sale 70.72 12,500 883,954 65,531 Nov 03 04:05 PM Sinha Uma Chief Scientific Officer Oct 29 Sale 72.42 5,000 362,099 321,525 Oct 30 04:55 PM Valle Franco Senior Vice President, Finance Oct 08 Option Exercise 7.24 5,199 37,641 5,199 Oct 09 05:23 PM Valle Franco Senior Vice President, Finance Oct 08 Sale 74.85 5,199 389,151 0 Oct 09 05:23 PM Valle Franco Senior Vice President, Finance Oct 07 Option Exercise 7.24 5,000 36,200 5,444 Oct 09 05:23 PM Valle Franco Senior Vice President, Finance Oct 07 Sale 75.08 5,444 408,748 0 Oct 09 05:23 PM Sinha Uma Chief Scientific Officer Oct 01 Sale 52.35 4,831 252,923 326,525 Oct 02 07:43 PM Sinha Uma Chief Scientific Officer Sep 30 Sale 52.03 169 8,794 331,356 Oct 02 07:43 PM Fox Jonathan C See Remarks Sep 17 Sale 50.16 5,767 289,259 377,673 Sep 18 04:06 PM Fox Jonathan C See Remarks Sep 16 Sale 50.16 3,122 156,610 383,440 Sep 16 06:35 PM Fox Jonathan C See Remarks Sep 15 Sale 50.06 1,000 50,064 386,562 Sep 16 06:35 PM Fox Jonathan C See Remarks Sep 14 Sale 50.00 111 5,550 387,562 Sep 16 06:35 PM Turtle Cameron Chief Business Officer Sep 10 Option Exercise 17.00 2,500 42,500 73,031 Sep 11 04:05 PM Turtle Cameron Chief Business Officer Sep 10 Sale 47.00 2,500 117,500 70,531 Sep 11 04:05 PM Turtle Cameron Chief Business Officer Aug 03 Option Exercise 13.20 5,000 66,000 80,531 Aug 05 07:45 PM Turtle Cameron Chief Business Officer Aug 03 Sale 39.94 10,000 399,450 70,531 Aug 05 07:45 PM Fox Jonathan C See Remarks Jul 07 Sale 50.00 5,000 250,000 387,673 Jul 09 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite